At the Silver Cancer Institute, we now do personalized molecular testing to determine which chemotherapy, natural substances, and immunotherapy works on your cancer. What this means to you is that we can determine, doing sophisticated molecular testing, what exact treatment is needed to kill your cancer. We no longer have to rely on statistical analysis to pick chemo which may or may not work on the patient.
Chemosensitivity testing provides the best information and guidance about the treatment and in particular what treatment may be best suited to the individual in clinical practice.Read More
The lab I use identifies tumor cells and isolates them from the samples for the following analysis:
- Viability testing of chemotherapy drugs.
- Genetic profiling for guidance about target therapies, such as monoclonal antibodies.
- Viability testing and identification of mechanisms of action, of natural substances which may be used as part of the complimentary treatment strategy.
I use a specialized lab composed of the most advanced and innovative technology that focuses on Molecular Oncology. They offer several different tests that are used for:
- The early detection and diagnosis of new cancers
- Monitoring of existing cancers.
- Prognosis about the risk of recurrence of previous cancers.
- The best of alternative and traditional therapy.
What Does Molecular Oncology Measure?
Unlike other tests, the genetic cancer testing we use is a very sensitive test that allows isolation and counting of circulating tumor cells in the blood sample. These are cancer cells that have broken away from the primary tumor and have entered the bloodstream.
The lab also evaluates genetic markers, 72 related genes, on the tumor cell to predict outcomes of treatment and prognosis. In addition, it can provide the following information:
No two cancers are alike even within an individual patient. Tumors may change over time. We are moving away from the concept that all cancers are the same. There is a new consensus that to truly fight cancer doctors need to understand it from the inside out, which means decoding its DNA and evaluate the biomarkers.
Until recently this highly sophisticated approach to cancer was virtually nonexistent. But fast moving developments in genetics and molecular biology are quickly changing that. The problem is that this testing isn't standard of care yet, but everyone does agree that it will be at some point.
In January 2015, the federal government launched a 250 million Precision Medicine Initiative to help build a data base that stores information and to support research at the National Cancer Institute. That funding alone, however, isn't nearly enough to usher in a new era of custom cancer care. What we need to do is have full data from all physicians which is the goal of the American Society of Clinical Oncology. ASCO recently announced it is creating a registry of patients who take drugs that are approved for a cancer other than the one for which they were cleared for by the FDA. We need to gather this information.
The problem is currently, less than 5% of the 1.6 million people diagnosed with cancer each year in Europe and the United States can take advantage of genetic testing. At most hospitals in this country this kind of testing is limited. If it is done there is always an out of pocket expense to the patient.
You need to have this revolutionary testing or you will never know how to attack your cancer. New sensitivity testing provides new insights revealing what actually works on your cancer. We provide the best medical protocols from all over the world with low dose metronomic chemotherapy, natural substances, and immunotherapies. If you would like more information please call us at (480) 860-2030.
Dean R. Silver, M.D., M.D. (H)